Table 1.
Drug compounds identified as primary hits with protective results in chemical library screening against influenza A/WSN/1933 (H1N1) virus.
| Drug | EC50 (μM)a | TC50 (μM)a | Selectivity index | Bioactivity | Serum concentration (μg/ml) [oral dose] |
|---|---|---|---|---|---|
| Mycophenolic acid | 0.24 | 170.00 | 708.00 | Anti-neoplastic | Mycophenolate mofetil: 10–50 [1 g] |
| Mycophenolate sodium: 26.1 [720 mg] | |||||
| Flufenamic acid | 6.30 | 79.16 | 12.60 | Anti-inflammatory, analgesic | 6–20 [200 mg] |
| Tolfenamic acid | 7.94 | 64.00 | 8.00 | Anti-inflammatory, analgesic | 4.1 [300 mg] |
| Mefenamic acid | 50.00 | 200.00 | 4.00 | Anti-inflammatory, analgesic | 10 [1 g] |
| Meclofenamate sodium | 45.00 | 100.00 | 2.00 | Anti-inflammatory, antipyretic | 4.8 [100 mg tds] |
| Ribavirin | 20.00 | 168.00 | 8.00 | Antiviral | 2.2 [4 weeks of 600 mg bd] |
| Mercaptopurine | 26.50 | 100.00 | 4.00 | Anti-neoplastic, purine anti-metabolite | 0.09 [50 mg/m2] |
| Pyrimethamine | 3.10 | 5.40 | 1.80 | Anti-malarial | 0.55 [1500/75 mg of sulfadoxine/pyrimethamine] |
| Emetine | 14.70 | 17.00 | 1.50 | Inhibits RNA, DNA, and protein synthesis | 0.001 [30 ml of syrup ipecac] |
| Estradiol | 20.00 | 75.00 | 3.00 | Estrogen | Not available |
a
Values represent activity against influenza A/WSN/1933 (H1N1) virus in MDCK cells.